| 摘要 |
<p>Provided herein are improved methods of treating subjects with adenosine A<SUB>1</SUB> receptor antagonists. The subject can be provided a composition that includes at least about 20-40 mg, preferably about 30 mg of an AA<SUB>1</SUB>RA, such as KW-3902 or a pharmaceutically acceptable salt, prodrug, ester, amide, or metabolite thereof to said subject, while maintaining a plasma C<SUB>max</SUB> of KW-3902 or its metabolites below about 600nM, preferably below about 550 nM, following administration.</p> |
